(Q43326259)

English

Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 November 2017

Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study (English)

1 reference

Europe PubMed Central

19 November 2017

1 reference

based on heuristic

inferred from title

irritable bowel syndrome

1 reference

based on heuristic

inferred from title

author name string

S Fukudo

1

1 reference

Europe PubMed Central

19 November 2017

M Hongo

2

1 reference

Europe PubMed Central

19 November 2017

H Kaneko

3

1 reference

Europe PubMed Central

19 November 2017

R Ueno

4

1 reference

Europe PubMed Central

19 November 2017

publication date

9 February 2011

1 reference

Europe PubMed Central

19 November 2017

Neurogastroenterology and Motility

1 reference

Europe PubMed Central

19 November 2017

23

1 reference

Europe PubMed Central

19 November 2017

6

1 reference

Europe PubMed Central

19 November 2017

544-e205

1 reference

Europe PubMed Central

19 November 2017

U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

Functional bowel disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

Constipation in long-term care

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

High prevalence of irritable bowel syndrome in medical outpatients in Japan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

Efficacy and safety of lubiprostone in patients with chronic constipation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

Asian consensus on irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

The usual medical care for irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

On closed testing procedures with special reference to ordered analysis of variance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

Lubiprostone--a novel treatment for irritable bowel syndrome with constipation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

Design of treatment trials for functional gastrointestinal disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01668.X

21 January 2018

Identifiers

10.1111/J.1365-2982.2011.01668.X

1 reference

Europe PubMed Central

19 November 2017

1 reference

Europe PubMed Central

19 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43326259&oldid=1986318884"